[A22-35] Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V
Last updated 06.10.2022
Project no.:
A22-35
Commission:
Commission awarded on 30.03.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Add-on treatment in adults with moderate to severe active autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-85 | Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35 | Commission completed |
Federal Joint Committee (G-BA)
06-10-2022 A G-BA decision was published.